PDCD2

Across TCGA pan-cancer cohorts, PDCD2 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated PDCD2 data layer compared with 2 for mutation status and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher PDCD2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated PDCD2 expression acts as an unfavorable survival marker, although some lineages such as SCLC and READ show a favorable association.

OV, LIHC, and ACC are the cancer types where PDCD2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	III,IV	0.786	0.882	.005	96	view →
LIHC	DFS	Median	All	0.472	0.610	<.001	95	view →
ACC	OS	Median	All	0.446	0.801	<.001	69	view →
ESCA	OS	Tertile	III,IV	0.363	0.693	.002	59	view →
KICH	DFS	Quartile	II,III,IV	0.384	0.894	.001	49	view →
DLBC	DFS	Median	III,IV	0.241	0.984	<.001	43	view →
CESC	DFS	Quartile	All	0.627	0.820	.005	40	view →
SCLC	OS	Median	All	0.767	0.509	.002	38	view →
READ	OS	Tertile	All	1.000	0.331	.004	37	view →
BRCA	OS	Median	II,III,IV	0.427	0.690	.002	25	view →
UCS	DFS	Tertile	IV	0.239	0.832	.024	24	view →
KIRP	DFS	Tertile	III,IV	0.118	0.607	.011	19	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

PDCD2–OV (OS)

Open the OV breakdown →